PT848720E - Antagonistas da actividade oncogenica da proteina mdm2 e sua utilizacao no tratamento de cancros - Google Patents
Antagonistas da actividade oncogenica da proteina mdm2 e sua utilizacao no tratamento de cancrosInfo
- Publication number
- PT848720E PT848720E PT96930195T PT96930195T PT848720E PT 848720 E PT848720 E PT 848720E PT 96930195 T PT96930195 T PT 96930195T PT 96930195 T PT96930195 T PT 96930195T PT 848720 E PT848720 E PT 848720E
- Authority
- PT
- Portugal
- Prior art keywords
- treatment
- oncogenic activity
- antagonists
- cancer
- mdm2 protein
- Prior art date
Links
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 title abstract 3
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 title abstract 3
- 230000002246 oncogenic effect Effects 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 239000005557 antagonist Substances 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 230000003042 antagnostic effect Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 150000007523 nucleic acids Chemical group 0.000 abstract 1
- 239000013603 viral vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4736—Retinoblastoma protein
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9510331A FR2738151B1 (fr) | 1995-09-04 | 1995-09-04 | Antagonistes de l'activite oncogenique de la proteine mdm2, et leur utilisation dans le traitement des cancers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT848720E true PT848720E (pt) | 2004-05-31 |
Family
ID=9482234
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT96930195T PT848720E (pt) | 1995-09-04 | 1996-09-02 | Antagonistas da actividade oncogenica da proteina mdm2 e sua utilizacao no tratamento de cancros |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US20030060432A1 (pt) |
| EP (1) | EP0848720B1 (pt) |
| JP (2) | JPH11511980A (pt) |
| KR (1) | KR100592916B1 (pt) |
| AT (1) | ATE257711T1 (pt) |
| AU (1) | AU722782B2 (pt) |
| BR (1) | BR9610386A (pt) |
| CA (1) | CA2228667C (pt) |
| CZ (1) | CZ298806B6 (pt) |
| DE (1) | DE69631335T2 (pt) |
| DK (1) | DK0848720T3 (pt) |
| ES (1) | ES2210386T3 (pt) |
| FR (1) | FR2738151B1 (pt) |
| HU (1) | HU223597B1 (pt) |
| IL (1) | IL123514A (pt) |
| NO (1) | NO319160B1 (pt) |
| PT (1) | PT848720E (pt) |
| SK (1) | SK287127B6 (pt) |
| WO (1) | WO1997009343A2 (pt) |
| ZA (1) | ZA967451B (pt) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9620028D0 (en) * | 1996-09-26 | 1996-11-13 | Ludwig Inst Cancer Res | Factors which interact with oncoproteins |
| US6013786A (en) * | 1997-08-22 | 2000-01-11 | Hybridon, Inc. | MDM2-specific antisense oligonucleotides |
| US6238921B1 (en) | 1998-03-26 | 2001-05-29 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of human mdm2 expression |
| EP0947494A1 (en) * | 1998-03-30 | 1999-10-06 | F. Hoffmann-La Roche Ag | Derivatives of phenoxy acetic acid and phenoxymethyltetrazole having antitumor activity |
| GB9819860D0 (en) | 1998-09-12 | 1998-11-04 | Zeneca Ltd | Chemical compounds |
| DE10109813A1 (de) * | 2001-03-01 | 2002-09-12 | Thomas Stanislawski | Tumor-Peptidantigen aus humanem mdm2 Proto-Onkogen |
| PL2118123T3 (pl) | 2007-01-31 | 2016-06-30 | Dana Farber Cancer Inst Inc | Stabilizowane peptydy p53 i ich zastosowania |
| KR101525754B1 (ko) | 2007-03-28 | 2015-06-09 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 스티칭된 폴리펩티드 |
| WO2009009587A2 (en) * | 2007-07-09 | 2009-01-15 | Board Of Regents Of The University Of Nebraska | Apoptosis-modulating protein therapy for proliferative disorders and nanoparticles containing the same |
| WO2011098262A2 (en) | 2010-02-09 | 2011-08-18 | Universität Bremen | P19arf, hmga2 and mdm2 for use in the diagnosis and treatment of aberrant cell growth |
| RU2615143C2 (ru) | 2010-03-24 | 2017-04-04 | Адвирна | Самодоставляющие PHKi соединения уменьшенного размера |
| CA2807685C (en) | 2010-08-13 | 2020-10-06 | Aileron Therapeutics, Inc. | P53 derived peptidomimetic macrocycle |
| TW201806968A (zh) | 2011-10-18 | 2018-03-01 | 艾利倫治療公司 | 擬肽巨環化合物 |
| BR112014020103A2 (pt) | 2012-02-15 | 2018-10-09 | Aileron Therapeutics, Inc. | macrociclos peptidomiméticos |
| CA2864120A1 (en) | 2012-02-15 | 2013-08-22 | Aileron Therapeutics, Inc. | Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles |
| KR20150082307A (ko) | 2012-11-01 | 2015-07-15 | 에일러론 테라퓨틱스 인코포레이티드 | 이치환 아미노산 및 이의 제조 및 사용 방법 |
| CN113151180A (zh) | 2013-12-02 | 2021-07-23 | 菲奥医药公司 | 癌症的免疫治疗 |
| US11279934B2 (en) * | 2014-04-28 | 2022-03-22 | Phio Pharmaceuticals Corp. | Methods for treating cancer using nucleic acids targeting MDM2 or MYCN |
| SG10201902598VA (en) | 2014-09-24 | 2019-04-29 | Aileron Therapeutics Inc | Peptidomimetic macrocycles and formulations thereof |
| MX2017003797A (es) | 2014-09-24 | 2017-06-15 | Aileron Therapeutics Inc | Macrociclos peptidomimeticos y usos de los mismos. |
| US10253067B2 (en) | 2015-03-20 | 2019-04-09 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
| CN108368161A (zh) | 2015-09-10 | 2018-08-03 | 艾瑞朗医疗公司 | 作为mcl-1调节剂的拟肽大环化合物 |
| CN109152843A (zh) | 2016-05-20 | 2019-01-04 | 豪夫迈·罗氏有限公司 | Protac抗体缀合物及其使用方法 |
| CA3071105A1 (en) * | 2017-07-27 | 2019-01-31 | Nomocan Pharmaceuticals Llc | Antibodies to m(h)dm2/4 and their use in diagnosing and treating cancer |
| WO2020023502A1 (en) | 2018-07-23 | 2020-01-30 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
| AU2019427766A1 (en) * | 2019-01-30 | 2021-09-16 | Nomocan Pharmaceuticals Llc | Antibodies to M(H)DM2/4 and their use in diagnosing and treating cancer |
| WO2023056069A1 (en) | 2021-09-30 | 2023-04-06 | Angiex, Inc. | Degrader-antibody conjugates and methods of using same |
| WO2024240858A1 (en) | 2023-05-23 | 2024-11-28 | Valerio Therapeutics | Protac molecules directed against dna damage repair system and uses thereof |
| CN120884603A (zh) * | 2024-04-28 | 2025-11-04 | 上海雅义生物医药科技有限公司 | 一种抑制mdm2和mdm4基因扩增的三链形成寡核苷酸序列及其应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5411860A (en) * | 1992-04-07 | 1995-05-02 | The Johns Hopkins University | Amplification of human MDM2 gene in human tumors |
| DE69333202T2 (de) * | 1992-06-26 | 2004-03-18 | The Trustees Of Princeton University | Verfahren zur erkennung von krebszellen oder ihren vorstadien mittels p90 und p53-antikörper oder p90 und p53-sonden |
| FR2706486B1 (fr) * | 1993-06-16 | 1995-09-01 | Rhone Poulenc Rorer Sa | Séquences nucléiques, vecteurs les contenant, compositions pharmaceutiques et utilisations thérapeutiques. |
| US5770377A (en) * | 1994-07-20 | 1998-06-23 | University Of Dundee | Interruption of binding of MDM2 and P53 protein and therapeutic application thereof |
-
1995
- 1995-09-04 FR FR9510331A patent/FR2738151B1/fr not_active Expired - Fee Related
-
1996
- 1996-09-02 KR KR1019980701598A patent/KR100592916B1/ko not_active Expired - Fee Related
- 1996-09-02 JP JP9510900A patent/JPH11511980A/ja not_active Withdrawn
- 1996-09-02 WO PCT/FR1996/001340 patent/WO1997009343A2/fr not_active Ceased
- 1996-09-02 DE DE69631335T patent/DE69631335T2/de not_active Expired - Lifetime
- 1996-09-02 BR BR9610386-8A patent/BR9610386A/pt active Search and Examination
- 1996-09-02 EP EP96930195A patent/EP0848720B1/fr not_active Expired - Lifetime
- 1996-09-02 CZ CZ0063098A patent/CZ298806B6/cs not_active IP Right Cessation
- 1996-09-02 IL IL123514A patent/IL123514A/en not_active IP Right Cessation
- 1996-09-02 CA CA2228667A patent/CA2228667C/fr not_active Expired - Fee Related
- 1996-09-02 AT AT96930195T patent/ATE257711T1/de active
- 1996-09-02 HU HU9900406A patent/HU223597B1/hu not_active IP Right Cessation
- 1996-09-02 AU AU69334/96A patent/AU722782B2/en not_active Ceased
- 1996-09-02 US US09/029,327 patent/US20030060432A1/en not_active Abandoned
- 1996-09-02 ES ES96930195T patent/ES2210386T3/es not_active Expired - Lifetime
- 1996-09-02 DK DK96930195T patent/DK0848720T3/da active
- 1996-09-02 PT PT96930195T patent/PT848720E/pt unknown
- 1996-09-02 SK SK280-98A patent/SK287127B6/sk not_active IP Right Cessation
- 1996-09-03 ZA ZA967451A patent/ZA967451B/xx unknown
-
1998
- 1998-03-02 NO NO19980905A patent/NO319160B1/no not_active IP Right Cessation
-
2003
- 2003-12-01 US US10/724,225 patent/US20040209834A1/en not_active Abandoned
-
2007
- 2007-01-10 US US11/651,486 patent/US20080311608A1/en not_active Abandoned
-
2011
- 2011-05-02 JP JP2011102826A patent/JP2011225571A/ja active Pending
-
2013
- 2013-03-15 US US13/835,524 patent/US20140030319A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT848720E (pt) | Antagonistas da actividade oncogenica da proteina mdm2 e sua utilizacao no tratamento de cancros | |
| EP0695171A1 (en) | GONADOTROPINE CONTAINING FREEZER DRIED DROPS | |
| TR199802423T2 (xx) | Konsantre antikor terkibi. | |
| SE9704546D0 (sv) | Novel compounds | |
| UA43348C2 (uk) | Водна фармацевтична композиція, що включає фактор росту нерва (варіанти) та ліофілізований фармацевтичний склад | |
| FI973278A0 (fi) | Uudet farnesyylitransferaasin inhibiittorit, niiden valmistus ja niitä sisältävät farmaseuttiset valmisteet | |
| ZA988585B (en) | Pharmaceutical compositions containing plasma protein. | |
| AUPP589598A0 (en) | Novel peptides | |
| FI954612L (fi) | Uusia imidatsolidiinejä, jotka on substituoitu heterosyklillä, niiden valmistusmenetelmä ja -välituotetteita, niiden käyttö lääkkeinä ja niitä sisältävät farmaseuttiset koostumukset | |
| ITFI930083A1 (it) | Composti pirrol-amidinici, processi di preparazione e composizioni farmaceutiche che li contengono. | |
| DE69533704D1 (de) | Bradykinin-antagonist peptide mit n-substituierten glycinen | |
| AU4363199A (en) | Use of hmg proteins for the preparation of medicaments having cytotoxic activity | |
| BG103968A (en) | Pharmaceutical antiviral composition containing glycirricinic acid and at least one protein with antiviral activity | |
| PT1228097E (pt) | Actividade antimicrobiana do primeiro grupo cationico da lactoferrina humana | |
| FI954986L (fi) | Uudet, suun kautta annettavat, syklosporiinia sisältävät farmaseuttiset valmisteet | |
| PT1024809E (pt) | Utilizacao de agentes de imunomodulacao | |
| FI972170A7 (fi) | Peptidejä, jotka kykenevät sitoutumaan GAP-proteiinin SH3-domeeniin, n äitä peptidejä koodittavia nukleotidisekvenssejä, niiden valmistus ja käyttö | |
| FR2718451B1 (fr) | Dérivés de peptides boroniques, leur préparation et leur application en thérapeutique. | |
| EE03996B1 (et) | Farmatseutilised kompositsioonid, nende valmistamismeetod ja kasutamine | |
| MX9709453A (es) | Composicion farmaceutica oral de compuestos de piperidinoalcanol en forma de solucion. | |
| PL336897A1 (en) | Novel salts of bpc peptides, pharmaceutic compositions conatining them and method of obtaining such salts | |
| IT1290910B1 (it) | 2-amminotetralina otticamente attiva, procedimento per la sua preparazione e composizioni farmaceutiche che la contengono, attive | |
| FI971872L (fi) | Proteiinikoostumus ja sen valmistus ja käyttö sekä sitä sisältävät valmisteet ja näiden valmistus | |
| DE69733026D1 (de) | Cyclin e spezifische konstrukte und komplexe | |
| IT1230858B (it) | Derivato di idrossiprolina, sua preparazione e composizioni farmaceutiche che lo contengono. |